PT236 – Dr. Carl Hart – Drugs: Honesty, Responsibility, and Logic

If you’re a regular listener of Psychedelics Today, you know how much Joe loved Dr. Carl Hart’s newest book and testament to responsible, out-of-the-closet drug use: Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear. In this episode, Joe and Kyle get to sit down and talk with the man himself for nearly …

Psychedelic Exceptionalism and Reframing Drug Narratives: An Interview with Dr. Carl Hart

By Sean Lawlor Dr. Carl Hart is neuropsychopharmacologist and Chair of Columbia University’s Department of Psychology. His research, which focuses on the behavioral and neuropsychological effects of psychoactive drugs in humans, has been published widely in academic journals, and Dr. Hart has discussed his research on numerous shows including Democracy Now!, The O’Reilly Factor, and …

PT342 – Spencer Hawkswell – The Right to Psilocybin in Canada: TheraPsil’s Charter Challenge

In this episode, Director of Corporate Communications Victoria Dekker records her first PT podcast; breaking some big news with the CEO of TheraPsil, Spencer Hawkswell. Nearly two years ago, TheraPsil helped four Canadians suffering from end-of-life distress access legal psilocybin under a Section 56 exemption, but due to these exemptions expiring and the new Co-Ministers of Health (Jean-Yves Duclos and Carolyn Bennett) having other priorities, these patients and other hopeful patients have lost access to their medicine. So just this week, TheraPsil has backed a charter challenge effectively suing the Canadian government, stating that closing these exemptions violates Canadians’ Section 7 charter rights to “life, liberty and security of person,” and launched a fundraiser to help with this upcoming battle. Hawkswell discusses the creation of TheraPsil and how they help patients through this process; the current (and complicated) ways patients access psilocybin; how Canada’s Special Access Program works; how mirroring cannabis legislation is the best place to start with psilocybin; the story of Thomas Hartle, the first patient to be granted legal access to psilocybin through TheraPsil’s efforts; and TheraPsil’s just-launched Project Solace, where people who have received SAP (or Section 56) access can report back on their experience with both the medicine and the process.